LONDON - With the capital markets closed, partnering is the only route to survival for biotechnology companies running out of cash. But doing deals is getting harder, with more due diligence, less interest in platform technologies and early stage products, and little appetite for drugs with novel mechanisms of action. (BioWorld International) Read More
